Skip to main content
Have a personal or library account? Click to login
Future Directions in Cardiac Amyloidosis Cover

Future Directions in Cardiac Amyloidosis

Methodist DeBakey Cardiovascular Journal
Volume 18 (2022): Issue 2
By:   
Open Access
|Mar 2022
Figures & tables

Figures & Tables

Figure 1

Potential future directions in cardiac amyloidosis. TTR: transthyretin; mAb: monoclonal antibody; CRISPR: clustered regularly interspaced short palindromic repeats; TAH: total artificial heart; AL: light chain amyloidosis; AI: artificial intelligence

DOI: https://doi.org/10.14797/mdcvj.1071 | Journal eISSN: 1947-6108
Journal RSS Feed
Language: English
Page range: 73 - 77
Submitted on: Dec 3, 2021
Accepted on: Feb 2, 2022
Published on: Mar 14, 2022
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
cardiac amyloidosis,
transthyretin cardiomyopathy,
light-chain amyloidosis,
antifibril therapy

© 2022 Barry Trachtenberg, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.

Volume 18 (2022): Issue 2
Previous article
Next article